SCHEMBL5475765

SCHEMBL5475765

O=c1[nH]nc2cc(C=Cc3ccc(Cl)cc3)c3ccccc3n12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 10/20 0.54
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CNR1 P21554 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37
TUBA3E Q6PEY2 1/20 0.37
TUBA1A Q71U36 1/20 0.37
TUBA1C Q9BQE3 1/20 0.37
TUBB6 Q9BUF5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475762 1.00 CHEK1 (0.54) CHEK1MAOAMAOBCNR1RAB9A
SCHEMBL5483336 0.76 CHEK1 (0.68) CHEK1RAB9AMAP3K7JAK2KDR
SCHEMBL5470155 0.72 CHEK1 (0.70) CHEK1RAB9AMAP3K7JAK2KDR
SCHEMBL14492136 0.72 CHEK1 (0.61) CHEK1MAP3K7JAK2KDRGRM2
SCHEMBL5767059 0.72 SMN1; SMN2 (0.51) MAOAMAOBCNR1RAB9ANPC1
SCHEMBL5470798 0.71 CHEK1 (1.00) CHEK1
SCHEMBL5478918 0.70 CHEK1 (0.67) CHEK1MAP3K7JAK2KDRGRM2
SCHEMBL5468928 0.68 CHEK1 (0.68) CHEK1
SCHEMBL5476236 0.64 CHEK1 (0.54) CHEK1RAB9AMAP3K7JAK2KDR
SCHEMBL5497035 0.64 CHEK1 (0.62) CHEK1MAP3K7JAK2KDRGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US claimed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149560-A1 Novel fused triazolones and the uses thereof TP53, BRCA1, KLK3 CHEK1 13/4885MAOA 2467/4885MAOB 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.